Cardiology

Certain SGLT2 inhibitors, GLP-1 RAs for T2DM also cut CV risk

(HealthDay)—Certain sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) demonstrate significant cardiovascular (CV) benefit and should be used for reducing CV risk ...

Medical research

Uncovering the whole story in diabetes

More than 400 million people worldwide suffer from type 2 diabetes, a disease characterised by increased blood glucose levels, because the body's normal way of controlling insulin release breaks down.

Diabetes

Improved rescue kits for people with diabetes, hypoglycemia

Being with someone who has diabetes and needs immediate care to avoid a coma can be a frightening situation. Even worse, current products and injection kits to help in those emergencies can be complicated to use.

Diabetes

mAb glucagon receptor blocker suitable for further development

(HealthDay)—The glucagon receptor blocker REGN1193, a fully human monoclonal antibody, seems safe and tolerable enough for further development, according to a study published online July 28 in Diabetes, Obesity and Metabolism.

Diabetes

Similar defects ID'd for T2DM, chronic pancreatitis and diabetes

(HealthDay)—Patients with type 2 diabetes and those with diabetes secondary to chronic pancreatitis have similarly impaired α-cell responses to oral glucose ingestion and hypoglycemia, according to a study published online ...

Diabetes

For diabetics, nasal powder fixed severe low blood sugar

(HealthDay)—For many people with diabetes, low blood sugar levels are a serious health risk, but researchers report that a new nasal powder quickly reverses the effects of this dangerous condition.

Medical research

Research opens the door to improved drugs for type 2 diabetes

Type 2 diabetes, a prolific killer, is on a steep ascent. According to the World Health Organization, the incidence of the condition has grown dramatically from 108 million cases in 1980 to well over 400 million today. The ...

page 3 from 7